Leitfaden für Rettungs- und Einsatzdienste bei Ereignissen mit chemischen, biologischen Gefahrstoffen, mit radioaktiven Stoffen und ionisierender Strahlung
Biology, Diagnosis and Treatment, Epidemiology and Prevention
The purpose of the review was to assign a cause of death, to ascertain the fac-tors that contributed to the death and to identify any systemic issues that could be addressed to prevent future similar deaths. The perinatal mortality audit process in 2019 provided important insights and evidence-based... recommendations that can be used both to address system errors and barriers and to identify and praise points of strength. The aim is to pro-vide recommendations for better care for mothers and their infants during pregnancy, childbirth and the neonatal period and improve the quality of care provided throughout the health system.
more
Working towards better COVID-19 outcomes in the WHO European Region.From the first COVID-19 cases in Europe reported on
24 January 2020, the pandemic reached 1 million cases
within 3 months, 10 million cases within 8 months, and
100 million cases in Europe alone within 2 years. Over
the course o...f its two years, COVID-19 has claimed over
1.6 million lives across Europe and Central Asia. The
World Health Organization (WHO) European Region has
accounted for close to a third of the cumulative global
COVID-19 cases and deaths.
more
Technical Guidelines for SARS-CoV-2 Vaccination: Third version
Los datos preliminares de eficacia se infirieron mediante un enfoque de “inmunogenicidad puente”, en el que los títulos neutralizantes obtenidos después de la vacuna en niños y niñas de 5 a 11 años se compararon con los títulos obtenidos en adolescentes de 16 a 25 años (en quienes se hab...a evaluado la eficacia).Entre los participantes sin evidencia de infección previa por SARS-CoV-2, hubo 3 casos de COVID-19 entre los 1.305 receptores de vacuna a partir de los 7 días de la segunda dosis y 16 entre los 663 receptores de placebo.
more
Le module de formation de niveau intermédiaire vise à soutenir la formation de personnel ou de volontaires, afin de fournir un fauteuil roulant manuel et un coussin appropriés aux filles, garçons, femmes et hommes qui nécessitent un soutien postural supplémentaire pour être en
mesure de se t...enir assis droit.
more
This handbook reflects and updates the work that ECLAC has done in recent decades to establish a methodology for estimating the economic consequences of a disaster, and thus determine the financing required to rebuild and return the affected area to normal. The handbook's third edition strengthens p...rocedures for estimating the effects of disasters, for distinguishing between losses and additional costs and systematizing the links that exist between different sectors of the economy
more
Abuses against Women and Girls with Psychosocial or Intellectual Disabilities in institutions in India
(für Asylsuchende, Geflüchtete und Anerkannte). Handreichung zum Infektionsschutz in Einrichtungen zur gemein-schaftlichen Unterbringung (EgU) von Asylbewerbern
Stand März 2022
e rapport conjoint de l’Organisation mondiale de la Santé(OMS) et du Programme des Nations unies pour lesétablissements humains (ONU-Habitat), intitulé La Face cachéedes villes : Mettre au jour et vaincre les inégalités en santé enmilieu urbain, montre que certains habitants des villes sont...particulièrement exposés à une multitude de maladies et deproblèmes de santé. Ce rapport propose des informations et des outils dont lespouvoirs publics et les responsables locaux peuvent se servirpour lutter contre les inégalités en santé dans leur ville. Il n’apas pour objectif de comparer les inégalités en santé entrepopulations rurales et citadines. De fait, étant différentes depar leur ampleur et leur distribution, les inégalités en santédans les zones urbaines appellent des actions spécifiques.
more
Monitoring is a crucial element in any successful programme. It is important to
know if health care facilities – and ultimately countries – are meeting the agreed
goals and objectives for preventing and managing cardiovascular diseases (CVD).
Monitoring is the on-going collection, management ...and use of information to
assess whether an activity or programme is proceeding according to plan and/
or achieving defined targets. Not all outcomes of interest can be monitored. Clear
outcomes must be identified that relate to the most important changes expected to result from the project and to what is realistic and measurable within the timescale of the project. Once these outcomes have been articulated, indicators can be chosen that best measure whether the desired outcomes are being met.
To allow progress to be monitored, this module provides a set of indicators on
CVD management. Agreeing on a set of indicators allows countries to compare
progress in CVD management and treatment across different districts or
subnational jurisdictions, as well as at a facility level, identify where performance
can be improved, and track trends in implementation over time. Monitoring
these indicators also helps identify problems that may be encountered so that
implementation efforts can be redirected.
This module starts from the collection of data at facility level, which is then
“transferred up” the system: facility-level data are aggregated at subnational level
to produce reports that allow tracking of facility and subnational performance over time and allow for comparison among facilities. National-level data are obtained through population-based surveys.
Implementing a monitoring system requires action at many levels. At national and
subnational levels, staff can determine how best to integrate data elements into
existing data collection systems – such as the routine service-delivery data that are collected through facility-level Health Management Information Systems (HMIS).
In the facility setting, personnel must be aware of what data are needed. Sample
data-collection tools are included, recognizing that countries use different datamanagement systems for HMIS, so the CVD monitoring tools will be adapted to work with the HMIS system being used by the country, such that the indicators can be collected with minimal disruption/work to existing systems and tools
more
Supplement Article
J Acquir Immune Defic Syndr Volume 75, Supplement 2, June 1, 2017 www.jaids.com
La dosis de refuerzo está indicada una vez transcurridos los 4 meses (120 días) de la última dosis del esquema inicial y será con vacuna de plataforma ARNm: Pfizer-BioNTech pediátrica a partir de los 5 años o Moderna para uso pediátrico a partir de los 6 años.
10 points basés sur l’expérience de terrain